Alcohol inhibits the metabolism of dimethyl fumarate to the active metabolite responsible for decreasing relapse frequency in the treatment of multiple sclerosis.
Dimethyl fumarate (DMF) is a first-line prodrug for the treatment of relapsing-remitting multiple sclerosis (RRMS) that is completely metabolized to monomethyl fumarate (MMF), the active metabolite, before reaching the systemic circulation. Its metabolism has been proposed to be due to ubiquitous es...
Main Authors: | Bing Yang, Robert B Parker, Bernd Meibohm, Zaid H Temrikar, Ashish Srivastava, S Casey Laizure |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0278111 |
Similar Items
-
Alcohol inhibits the metabolism of dimethyl fumarate to the active metabolite responsible for decreasing relapse frequency in the treatment of multiple sclerosis
by: Bing Yang, et al.
Published: (2022-01-01) -
Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
by: Roberto Bomprezzi
Published: (2015-01-01) -
Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
by: Ozel O, et al.
Published: (2019-12-01) -
Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
by: Ricardo Ginestal, et al.
Published: (2023-01-01) -
Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
by: Raed Alroughani, et al.
Published: (2021-01-01)